An expert Q&A with Suchira Ghosh and Eric Greenwald of Axinn, Veltrop & Harkrider LLP on how the US Supreme Court's decision in Sandoz v. Amgen, Inc. and other judicial interpretations of various provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) over the past year are likely to affect the filing and litigation strategies of biosimilar applicants and biologics manufacturers, and how these cases may impact the development trajectory of the nascent biosimilar industry in the US.